NCT03196947View on ClinicalTrials.gov

Safety and Pharmacokinetics of Rising Doses of APO010 in Relapsed/Refractory Multiple Myeloma Patients Selected by DRP

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

June 13, 2017

Primary Completion Date

January 16, 2020

Study Completion Date

January 16, 2020

Conditions
Relapsed/Refractory Multiple Myeloma
Interventions
DRUG

APO010

APO010 is given iv on D1, D8 and D15 followed by a one-week drug rest (cycle duration 4 weeks).

Trial Locations (1)

2100

University Hospital of Copenhagen, Copenhagen

Sponsors
All Listed Sponsors
collaborator

Smerud Medical Research International AS

OTHER

collaborator

Medical Prognosis Institute A/S

INDUSTRY

lead

Allarity Therapeutics

INDUSTRY

NCT03196947 - Safety and Pharmacokinetics of Rising Doses of APO010 in Relapsed/Refractory Multiple Myeloma Patients Selected by DRP | Biotech Hunter | Biotech Hunter